OptimizeRx's (OPRX) "Buy" Rating Reiterated at Roth Mkm

OptimizeRx (NASDAQ:OPRX - Get Free Report)'s stock had its "buy" rating reiterated by Roth Mkm in a research note issued to investors on Thursday,Benzinga reports. They currently have a $16.00 target price on the stock, down from their previous target price of $20.00. Roth Mkm's target price would suggest a potential upside of 294.09% from the company's previous close.

Other equities research analysts have also recently issued reports about the stock. Royal Bank of Canada lowered their price objective on shares of OptimizeRx from $17.00 to $14.00 and set an "outperform" rating on the stock in a research note on Friday, August 16th. B. Riley initiated coverage on shares of OptimizeRx in a research note on Thursday, July 25th. They set a "buy" rating and a $18.50 price objective for the company. Stifel Nicolaus decreased their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a "buy" rating for the company in a research note on Thursday. JMP Securities lowered their target price on OptimizeRx from $16.00 to $8.00 and set a "market outperform" rating for the company in a research note on Thursday. Finally, Barclays dropped their price target on shares of OptimizeRx from $11.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $10.42.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX traded down $2.09 during trading on Thursday, hitting $4.06. 1,962,988 shares of the stock were exchanged, compared to its average volume of 140,475. OptimizeRx has a 12-month low of $3.95 and a 12-month high of $16.65. The company has a market cap of $74.39 million, a PE ratio of -4.06 and a beta of 1.32. The company has a fifty day moving average price of $6.67 and a two-hundred day moving average price of $9.03. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.27.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Summit Securities Group LLC bought a new stake in shares of OptimizeRx during the second quarter valued at about $25,000. BNP Paribas Financial Markets boosted its holdings in shares of OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock valued at $28,000 after acquiring an additional 2,414 shares in the last quarter. Quest Partners LLC increased its stake in shares of OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company's stock valued at $76,000 after acquiring an additional 9,739 shares during the period. Connors Investor Services Inc. boosted its stake in OptimizeRx by 15.1% during the 2nd quarter. Connors Investor Services Inc. now owns 19,107 shares of the company's stock valued at $191,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of OptimizeRx during the 2nd quarter valued at $282,000. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.